Davern Capital Partners, LP
CIK 0002003147 · NY, NY · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$586.5M
2026 Q2
Positions
15
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
86.8%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
BNTX
BIONTECH SE
12.0%
ROIV
ROIVANT SCIENCES LTD
11.7%
RPRX
ROYALTY PHARMA PLC
11.0%
IONS
IONIS PHARMACEUTICALS INC
10.8%
INSM
INSMED INC
10.2%
REGN
REGENERON PHARMACEUTICALS
9.8%
LEGN
LEGEND BIOTECH CORP
5.9%
ALNY
ALNYLAM PHARMACEUTICALS INC
5.8%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.